000 | 01910nam a2200397 i 4500 | ||
---|---|---|---|
001 | 2133324 | ||
003 | StDuBDS | ||
005 | 20231010110700.0 | ||
006 | m|||||o||d|||||||| | ||
007 | cr ||||||||||| | ||
008 | 190118s2019 enka fob 001|0|eng|d | ||
020 |
_a9781910797808 (PDF ebook) : _cNo price |
||
020 |
_z9781910797792 (pbk.) : _cNo price |
||
020 | _z9781910797808 | ||
040 |
_aStDuBDS _beng _cStDuBDS _erda _epn |
||
060 | 4 | _aWH 525 | |
100 | 1 |
_aMesa, Ruben A., _eauthor. |
|
245 | 1 | 0 |
_aMyeloproliferative neoplasms / _h[e-book] |
250 | _aFirst edition. | ||
264 | 1 |
_aAbingdon, Oxford : _bKarger, _c2019. |
|
300 |
_a1 online resource (115 pages) : _billustrations (colour). |
||
490 | 1 | _aFast facts | |
500 | _aAlso issued in print: 2019. | ||
504 | _aIncludes bibliographical references and index. | ||
520 | 8 | _aPresentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as understanding of the underlying molecular basis for these disorders emerges. Appropriate management is increasingly informed by accurate risk stratification founded on understanding of cytogenetic and molecular markers, as well as the clinical presentation. | |
521 | _aSpecialized. | ||
588 | _aDescription based on online resource; title from PDF title page (viewed on January 17, 2023). | ||
650 | 0 | _aMyeloproliferative disorders. | |
650 | 0 |
_aHematopoietic system _xCancer. |
|
650 | 2 | _aMyeloproliferative Disorders. | |
650 | 2 | _aHematopoietic System. | |
650 | 2 | _aHematologic Neoplasms. | |
700 | 1 |
_aHarrison, Claire _q(Claire N.), _eauthor. |
|
830 | 0 | _aFast facts. | |
856 | 4 | 0 |
_uhttps://app.kortext.com/Shibboleth.sso/Login?entityID=https://idp.eng.nhs.uk/openathens&target=https://app.kortext.com/borrow/2133324 _yEligible NHS OpenAthens account holders click here for access |
999 |
_c96862 _d96862 |